Gilead Says 11% of Prior Non-Responders Cured in Hepatitis Trial
This article is for subscribers only.
Gilead Sciences Inc.’s experimental hepatitis C drug cleared the virus in 11 percent of patients who hadn’t responded to prior treatment, the company said today.
A combination of Gilead’s 7977 drug and the antiviral ribavirin cleared 1 out of 9 so-called “null responder” patients with the most common genotype 1 form of the virus four weeks after ending treatment, the Foster City, California-based company said today in a poster at the European Association for the Study of Liver meeting in Barcelona. The cure rate compares with 88 percent of patients who had never been treated before.